REPLY
23.10.2018 13:02:04 CEST | Business Wire | Press release
Today Oracle awarded Business Reply with its 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud.
The Oracle Excellence Awards for Specialized Partner of the Year – EMEA recognizes Business Reply for their outstanding work in driving customer success with ERP Cloud offering. Oracle partners accelerate innovation and customers upgrade to the cloud. From business planning and implementation, to connectivity and data center services, Oracle PartnerNetwork (OPN) members provide the support and services needed to maximize the value of Oracle Cloud solutions for customers’ organization, and it offers its members unique opportunities to accelerate and expand their business.
Business Reply is a Platinum Cloud Select level member of Oracle PartnerNetwork (OPN). Business Reply was presented the 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud for demonstrating an outstanding and innovative solution based on Oracle products.
The Oracle Excellence Awards for Specialized Partner of the Year – EMEA encourages innovation by Oracle PartnerNetwork (OPN) members, who use Oracle’s products and technology to create value for customers and generate new business potential.
Business Reply, the Reply Group company focused on Oracle SAAS, has been able to see the advantages of the Cloud in time and it has helped European companies to grasp the potential of the cloud, giving life to ambitious ERP cloud projects able to transform the business and services in depth.
Business Reply represents a point of reference among companies for ERP and Corporate Governance services, and it guarantees a deep knowledge of business processes together with a strong technical expertise on all Oracle application solutions.
Filippo Rizzante, CTO at Reply, said, “We are absolutely delighted to have won the award for Specialized Partner of the Year: ERPM Cloud – EMEA. Continuous investments in innovation and research & development have been critical to the creation of the most innovative ERP Cloud projects on Oracle technologies. The relationship and collaboration with Oracle has been instrumental to the success of Business Reply, enabling the team to maintain innovation as the Oracle platform evolves.”
“Business Reply has demonstrated an outstanding level of innovation in delivering proven, Oracle-based ERP Cloud solutions that solve our joint customers’ most critical business challenges,” said Javier Torres, Vice President Alliances & Channels Oracle EMEA. “We congratulate Business Reply in achieving the 2018 Oracle Excellence Award for Specialized Partner of the Year – EMEA in ERPM Cloud. This achievement is a testament to their dedication to excellence and to providing customers solutions that drive real business value and results.”
About Business Reply
Business Reply, the Reply Group company specialising in the creation of integrated systems based on Oracle application suites, is Oracle Platinum Cloud Select Partner. With over 18 years of experience and more than 80 completed projects, Business Reply represents a point of reference among companies for ERP and Corporate Governance services. Strongly oriented towards Digital Transformation, thanks to investments in innovation and research & development and a process of continuous training and specialization of its resources, Business Reply was the first Italian Oracle Partner to realize projects on Oracle ERP Cloud, OTM Cloud and Service Cloud. In 2018, Business Reply has been recognized by Oracle: “Cloud Excellence Implementer”, for providing superior customer experience through successful Oracle HCM Cloud Services implementations.
About Oracle PartnerNetwork
Oracle PartnerNetwork (OPN) is Oracle's partner program that provides partners with a differentiated advantage to develop, sell and implement Oracle solutions. OPN offers resources to train and support specialized knowledge of Oracle’s products and solutions and has evolved to recognize Oracle’s growing product portfolio, partner base and business opportunity. Key to the latest enhancements to OPN is the ability for partners to be recognized and rewarded for their investment in Oracle Cloud. Partners engaging with Oracle will be able to differentiate their Oracle Cloud expertise and success with customers through the OPN Cloud program – an innovative program that complements existing OPN program levels with tiers of recognition and progressive benefits for partners working with Oracle Cloud. To find out more visit: http://www.oracle.com/partners .
Trademarks
Oracle and Java are registered trademarks of Oracle and/or its affiliates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181023005365/en/
Contact:
Reply Fabio Zappelli f.zappelli@reply.com or Aaron Miani a.miani@reply.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom